These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28337954)

  • 41. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
    Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy--a single-arm phase II study.
    Shawky H; Galal S
    J Egypt Natl Canc Inst; 2014 Dec; 26(4):195-202. PubMed ID: 25467387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
    de Boo LW; Jóźwiak K; Joensuu H; Lindman H; Lauttia S; Opdam M; van Steenis C; Brugman W; Kluin RJC; Schouten PC; Kok M; Nederlof PM; Hauptmann M; Linn SC
    Br J Cancer; 2022 Jun; 126(10):1401-1409. PubMed ID: 35124703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
    Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
    Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
    Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
    J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
    Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
    Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
    Nitz U; Gluz O; Clemens M; Malter W; Reimer T; Nuding B; Aktas B; Stefek A; Pollmanns A; Lorenz-Salehi F; Uleer C; Krabisch P; Kuemmel S; Liedtke C; Shak S; Wuerstlein R; Christgen M; Kates RE; Kreipe HH; Harbeck N;
    J Clin Oncol; 2019 Apr; 37(10):799-808. PubMed ID: 30785826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
    Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
    Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response-guided neoadjuvant chemotherapy for breast cancer.
    von Minckwitz G; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Eiermann W; Gerber B; Hanusch C; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Kümmel S; Paepke S; Schneeweiss A; Untch M; Zahm DM; Mehta K; Loibl S
    J Clin Oncol; 2013 Oct; 31(29):3623-30. PubMed ID: 24002511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.
    Kószó R; Sántha D; Büdi L; Erfán J; Győrfy K; Horváth Z; Kocsis J; Landherr L; Hitre E; Máhr K; Pajkos G; Pápai Z; Kahán Z
    Pathol Oncol Res; 2017 Jul; 23(3):505-511. PubMed ID: 27771885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Addition of Capecitabine in Breast Cancer First-line Chemotherapy Improves Survival of Breast Cancer Patients.
    Xu D; Chen X; Li X; Mao Z; Tang W; Zhang W; Ding L; Tang J
    J Cancer; 2019; 10(2):418-429. PubMed ID: 30719136
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study.
    Zhang X; Zhou Y; Mao F; Lin Y; Guan J; Sun Q
    Med Oncol; 2015 Oct; 32(10):240. PubMed ID: 26346724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer.
    Xi X; Huang X; Yuan H; Ni J; Yang F
    J Healthc Eng; 2022; 2022():7430775. PubMed ID: 35265304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin.
    Bujko K; Glimelius B; Valentini V; Michalski W; Spalek M
    Eur J Surg Oncol; 2015 Jun; 41(6):713-23. PubMed ID: 25911110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.